COMPREHENSIVE MULTITARGET STRATEGY FOR TYPE 1 DIABETES AND ASSOCIATED NEUROLOGICAL/SLEEP DISORDERS (DANS): INTEGRATING STEM-CELL-DERIVED ISLET REPLACEMENT, IMMUNE MODULATION, AND NEURO-CIRCADIAN THERAPEUTICS

Type 1 diabetes (T1D) manifests as a systemic disorder, with hyperglycemia driving interconnected pathways of neuroinflammation, oxidative stress, β-cell loss, orexin deficits, and circadian disruption. These mechanisms underpin Diabetes-Associated Neurological and Sleep Disorders (DANS), exacerbating metabolic instability alongside neuropathy, cognitive decline, and sleep dysregulation. To address this holistically, NewCelX and its NCEL-101/IsletRx stem-cell-derived islet platform, in strategic collaboration with Eledon Pharmaceuticals, pioneers tegoprubart (anti-CD40L mAb, formerly AT-1501)mediated immune protection. This enables durable graft survival and potential T1D functional cure, as evidenced by clinical insulin independence without calcineurin inhibitor toxicities, thereby restoring glycemic control to mitigate DANS progression. Synergizing with this regenerative core, Aexon Labs and its multitarget dihydroquinazoline/dihydrobenzoxazine/dihydrobenzothiazine platform (featuring DOXA compounds for orexin restoration, Sig-1R modulation, CTSS/CTSL inhibition, and SGLT2/adiponectin targeting) directly combats DANS through anti-inflammatory, neuroprotective, and metabolic actions—reducing neuroinflammation/oxidative stress, preserving β-cell/neural integrity, enhancing glucose control/insulin sensitivity, and normalizing circadian/energy/cognitive functions. Preclinical data unify these elements: orexin A preconditioning enhances islet graft outcomes (e.g., insulin sensitivity, GLUT-4 expression, β-cell survival) while inhibiting high-glucose-induced NLRP3 inflammasome activation in endothelium via SIRT1-dependent suppression of ROS/NOX4/TxNIP/HMGB1 and IL-1β/IL-18. Sig-1R/DOXA modulation further amplifies neuroprotection in diabetic complications, complementing tegoprubart’s anti-CD40L blockade—which curbs NLRP3linked inflammation—thus safeguarding grafts and alleviating DANS. This integrated framework—stem-cell regeneration + targeted immunomodulation + neuro-circadian therapeutics—transforms T1D/DANS management, accelerating clinical translation, regulatory progress, and scalable therapies.